Pregnancy and acromegaly.
Ammar MuhammadSebastian J NeggersAart J van der LelyPublished in: Pituitary (2017)
Acromegaly is a disorder that is characterized by changes in growth hormone (GH), insulin-like growth factor-1 (IGF-1) and insulin concentrations and actions. All these hormones are important in pregnancy as well. In principle, the fetal-placental collaboration between mother and child more-or-less takes over the control over GH and IGF-1, not only in normal physiology but also to a certain extend in acromegaly. When medication for the high GH levels or actions is continued during pregnancy, both dopamine agonists, somatostatin analogs and GH receptor antagonists have been used and the available data suggest that there are no adverse consequences on mother or fetus to date. However, it is strongly advised to stop any medical intervention during pregnancy until more data are available on the safety of these compounds. Also, medical treatment is not needed as tumor size and disease activity are not reported to escape.
Keyphrases
- growth hormone
- disease activity
- rheumatoid arthritis
- healthcare
- systemic lupus erythematosus
- electronic health record
- rheumatoid arthritis patients
- ankylosing spondylitis
- type diabetes
- preterm birth
- randomized controlled trial
- big data
- juvenile idiopathic arthritis
- pregnancy outcomes
- mental health
- adverse drug
- pregnant women
- molecular docking
- uric acid
- combination therapy
- emergency department
- adipose tissue
- artificial intelligence
- cell proliferation
- machine learning
- neuroendocrine tumors
- insulin resistance